NXTC

Nextcure Inc

6.31

Oct 30 • 3:59 PM ET -0.22 (-3.30%)

6.31

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Peers: PYXS KYNB STRO MGNX CTMX BOLT ALXO ZYME HOWL CMPX

| Held by: VTI VXF IWC DFMC DFAC

Scroll to Statements

Index	-
Market Cap	28.88M
Enterprise Value	13.08M
Income	-42.75M
Sales	0.00M
Book/sh	2.99
Cash/sh	4.39
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	40
IPO	May 09, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.11
P/C	1.44
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.47
Current Ratio	3.47
Debt/Eq	0.35
LT Debt/Eq	0.30
Option/Short	No / Yes

EPS (ttm)	-10.59
EPS next Y	-1.38
EPS next Q	-0.90
EPS this Y	67.74%
EPS next Y	78.23%
EPS next 5Y	60.40%
EPS past 3/5Y	15.29% -4.25%
Sales past 3/5Y	- -
EPS Y/Y TTM	59.14%
Sales Y/Y TTM	-
EPS Q/Q	75.16%
Sales Q/Q	-
Earnings	Aug 06 AMC
EPS/Sales Surpr.	-43.59% -

Insider Own	16.30%
Insider Trans	78.30%
Inst Own	48.11%
Inst Trans	-6.43%
ROA	-121.60%
ROE	-195.22%
ROIC	-271.38%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	4.98%
SMA50	3.48%
SMA200	-19.59%
Trades

Shs Outstand	4.07M
Shs Float	3.83M
Short Float	5.77%
Short Ratio	1.35
Short Interest	0.22M
52W High	15.74 -59.91%
52W Low	1.55 307.10%
Volatility	13.71% 14.91%
ATR (14)	0.79
RSI (14)	54.30
Beta	1.27
Rel Volume	0.12
Avg Volume	164.24K
Volume	19,203

Perf Week	26.71%
Perf Month	27.22%
Perf Quarter	43.41%
Perf Half Y	-32.59%
Perf YTD	-55.53%
Perf Year	-48.49%
Perf 3Y	-52.63%
Perf 5Y	-93.60%
Perf 10Y	-
Recom	1.00
Target Price	20.00
Prev Close	6.53
Price	6.31
Change %	-3.30%

Consensus

Strong Buy

Avg. Price Target

$20.00

Implied Upside

+217.0%

Analysts12incl. previous ratings

Rating Distribution8 Buy · 3 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 07, 2025	Upgrade	LLadenburg Thalmann	Neutral → Buy	$18	+185.3%
Nov 04, 2022	Downgrade	LLadenburg Thalmann	Buy → Neutral
Mar 01, 2022	Initiated	LLadenburg Thalmann	Buy	$16	+153.6%
Mar 05, 2021	Upgrade	TTruist	Hold → Buy	$19	+201.1%
Jan 15, 2021	Downgrade	BBofA Securities	Neutral → Underperform	$10	+58.5%
Jul 16, 2020	Upgrade	TThe Benchmark Company	Hold → Buy	$17	+169.4%
Jul 13, 2020	Downgrade	SSunTrust	Buy → Hold
Jul 13, 2020	Downgrade	RROTH Capital	Buy → Neutral
Jun 01, 2020	Downgrade	TThe Benchmark Company	Buy → Hold
Jun 01, 2020	Downgrade	BBofA/Merrill	Buy → Neutral	$62 → $40	+533.9%
May 26, 2020	Initiated	JJMP Securities	Mkt Outperform	$55	+771.6%
Mar 24, 2020	Initiated	TThe Benchmark Company	Buy	$55	+771.6%
Mar 02, 2020	Initiated	RROTH Capital	Buy	$80	+1,167.8%
Jan 13, 2020	Initiated	SSunTrust	Buy	$78	+1,136.1%
Dec 05, 2019	Initiated	NNeedham	Buy
Nov 26, 2019	Initiated	BBTIG Research	Buy	$61	+866.7%
Jul 09, 2019	Initiated	BBofA/Merrill	Buy	$25	+296.2%
Jun 03, 2019	Initiated	PPiper Jaffray	Overweight	$26	+312.0%
Jun 03, 2019	Initiated	MMorgan Stanley	Overweight	$25	+296.2%

Aug-06-26 04:01PM	NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire) +6.48%
Jul-24-26 04:38PM	Halper Sadeh LLC is Investigating Whether VEEE, NXTC, TCBK, FHB are Obtaining Fair Deals for their Shareholders (PR Newswire) +20.75%
Jul-21-26 02:51PM	Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders? (PR Newswire) -5.37%
Jul-14-26 08:30AM	Surgical Infections Cost Hospitals Billions. One Under-the-Radar Biotech Player Might be About to Change That (FinanceWire) +201.83%
08:00AM	Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill (BioPharma Dive)
06:00AM	Loading…
06:00AM	NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy (GlobeNewswire)
Jun-04-26 08:00AM	NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers (GlobeNewswire)
Jun-01-26 08:00AM	NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 (GlobeNewswire) -45.48%
May-07-26 04:05PM	NextCure Provides Business Update and Reports First Quarter 2026 Financial Results (GlobeNewswire) -5.04%
May-04-26 07:05AM	NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers (GlobeNewswire)
Apr-21-26 10:15AM	NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 (GlobeNewswire) -6.24%
Apr-07-26 08:05AM	NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer (GlobeNewswire)
Mar-31-26 04:05PM	NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026 (GlobeNewswire) +7.88%
Mar-05-26 04:05PM	NextCure Provides Business Update and Reports Full Year 2025 Financial Results (GlobeNewswire)
Jan-23-26 07:00AM	NextCure Provides Business Update (GlobeNewswire) -5.77%
08:00AM	Loading…
Nov-20-25 08:00AM	NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-17-25 08:00AM	NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts (GlobeNewswire)
Nov-12-25 08:00AM	NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules (GlobeNewswire) +9.04%
Nov-11-25 09:55AM	Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect? (Zacks)
Nov-05-25 04:05PM	NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-16-25 08:05AM	NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States (GlobeNewswire) +27.75%
Sep-04-25 07:00AM	NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-07-25 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-24-25 04:05PM	Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta (GlobeNewswire) +17.30%
Jun-17-25 05:34AM	NextCure and Simcere partner to develop SIM0505 for solid tumours (Pharmaceutical Technology) -10.08%
Jun-16-25 07:05AM	NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 (GlobeNewswire) -26.27%
May-29-25 11:03PM	NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024 (Insider Monkey) +6.41%
04:05PM	NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 (GlobeNewswire)
May-01-25 04:05PM	NextCure Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) -7.81%
Apr-04-25 07:00AM	NextCure to Present at 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
04:05PM	Loading…
Mar-06-25 04:05PM	NextCure Provides Business Update and Reports Full Year 2024 Financial Results (GlobeNewswire) +5.20%
Jan-10-25 08:05AM	NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers (GlobeNewswire) -6.11%
Dec-10-24 08:05AM	NextCure Announces Acceptance of IND Application for LNCB74 (GlobeNewswire)
Nov-26-24 07:00AM	NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-19-24 08:05AM	Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta (GlobeNewswire)
Nov-08-24 06:18AM	NextCure goes all in on B7-H4, stopping other programs to challenge Big Pharma in ADC space (FierceBiotech.com)
Nov-07-24 04:05PM	NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 04:05PM	NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Oct-04-24 09:05AM	NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-16-24 08:05AM	NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 (GlobeNewswire)
Aug-01-24 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-20-24 04:10PM	NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire) +13.64% +8.00%
May-30-24 04:05PM	NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 (GlobeNewswire)
May-02-24 09:57PM	NXTC Stock Earnings: NextCure Misses EPS for Q1 2024 (InvestorPlace) +8.76%
04:05PM	NextCure Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 04:05PM	NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024 (GlobeNewswire) -5.88% -10.42%
Apr-08-24 07:00AM	NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024 (GlobeNewswire) -5.96%
Apr-04-24 07:05AM	NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board (GlobeNewswire) -10.00%
Apr-02-24 07:00AM	NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +7.79%
Mar-23-24 06:00AM	Wall Streets Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich (InvestorPlace)
Mar-21-24 10:54PM	NXTC Stock Earnings: NextCure Beats EPS for Q4 2023 (InvestorPlace) +19.15% +13.10%
11:22AM	NextCure to lay off 37% of staff, dial back research plans (BioPharma Dive)
08:55AM	NextCure Provides Business Update and Reports Full Year 2023 Financial Results (GlobeNewswire)
Mar-05-24 08:05AM	NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances (GlobeNewswire)
Jan-18-24 04:05PM	NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders (GlobeNewswire)
Dec-25-23 09:55AM	Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing (Zacks)
Dec-21-23 07:05AM	NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury (GlobeNewswire)
Dec-15-23 11:23AM	NextCure (NXTC) Down on Shelving Plans to Develop Candidate (Zacks) -5.13%
Dec-14-23 09:14AM	NextCure jettisons monoclonal antibody to focus on ADC aimed at same target (FierceBiotech.com) -19.31%
06:45AM	NextCure Provides Year-End Clinical Pipeline Updates (GlobeNewswire)
Nov-20-23 07:00AM	NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-15-23 04:05PM	NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML (GlobeNewswire) +5.93% -6.40%
Nov-07-23 12:00PM	All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy (Zacks)
Nov-02-23 06:07PM	NextCure Inc (NXTC) Reports Q3 2023 Financial Results (GuruFocus.com) +9.35%
04:05PM	NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-17-23 08:05AM	Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI) (GlobeNewswire)
Sep-26-23 04:05PM	NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimers Disease (GlobeNewswire)
Sep-12-23 08:05AM	A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC (GlobeNewswire)
Sep-07-23 04:05PM	NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen (GlobeNewswire)
Sep-05-23 04:05PM	Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease (GlobeNewswire)
Aug-31-23 07:00AM	NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jun-21-23 04:05PM	NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting (GlobeNewswire)
May-11-23 01:58PM	Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? (Simply Wall St.)
May-09-23 07:00AM	NextCure to Present at the JMP Securities Life Sciences Conference (GlobeNewswire) +7.41%
May-04-23 04:05PM	NextCure Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-11-23 07:00AM	NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-02-23 04:05PM	NextCure Provides Business Update and Reports Full Year 2022 Financial Results (GlobeNewswire)
Feb-07-23 07:00AM	NextCure to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Dec-02-22 10:59AM	Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-22-22 08:00AM	NextCure to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-16-22 08:09AM	NextCure, LegoChem Biosciences Ink Collaborative Pact For Antibody Drug Conjugates (Benzinga) -6.02%
Nov-15-22 04:30PM	NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates (GlobeNewswire)
Nov-07-22 08:05AM	NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) -13.64%
Nov-03-22 04:15PM	NextCure Provides Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire) -21.12%
09:15AM	NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-27-22 04:05PM	NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board (GlobeNewswire)
Oct-05-22 12:00PM	NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade (Zacks)
08:15AM	NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Oct-04-22 04:05PM	NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors (GlobeNewswire) +9.42%
Sep-22-22 08:00AM	NextCure to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire) -12.64%
Aug-22-22 06:23AM	With 37% ownership, NextCure, Inc. (NASDAQ:NXTC) has piqued the interest of institutional investors (Simply Wall St.) -5.45%
Aug-04-22 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire) +6.32%
Jul-06-22 08:00AM	NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation (GlobeNewswire)
Jun-27-22 08:00AM	NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM (GlobeNewswire)
Jun-25-22 10:26AM	We're Hopeful That NextCure (NASDAQ:NXTC) Will Use Its Cash Wisely (Simply Wall St.)
Jun-22-22 08:00AM	Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting (GlobeNewswire)
Jun-08-22 08:00AM	NextCure to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
May-11-22 08:17AM	NextCure, Inc.'s (NASDAQ:NXTC) Intrinsic Value Is Potentially 34% Above Its Share Price (Simply Wall St.)
May-05-22 04:05PM	NextCure Provides Business Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ADAR1 Capital Management, LLC	10% Owner	Oct 23 '26	Buy	4.83	5,626	27,170	728,045	Oct 27 07:36 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 27 '26	Buy	5.10	3,553	18,104	733,270	Oct 27 07:36 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 26 '26	Buy	5.03	1,672	8,418	729,717	Oct 27 07:36 PM
Simcere Zaiming, Inc.	Former 10% Owner	Aug 10 '26	Sale	6.16	30,000	184,800	308,636	Aug 12 11:35 AM
ADAR1 Capital Management, LLC	10% Owner	Jul 30 '26	Buy	4.93	292,850	1,444,746	686,116	Aug 03 05:53 PM
ADAR1 Capital Management, LLC	10% Owner	Jul 31 '26	Buy	4.94	36,303	179,375	722,419	Aug 03 05:53 PM
ADAR1 Capital Management, LLC	10% Owner	Jul 27 '26	Buy	5.00	7,798	38,985	383,456	Jul 29 06:18 PM
ADAR1 Capital Management, LLC	10% Owner	Jul 28 '26	Buy	4.95	6,400	31,677	389,856	Jul 29 06:18 PM
ADAR1 Capital Management, LLC	10% Owner	Jul 29 '26	Buy	5.00	3,410	17,050	393,266	Jul 29 06:18 PM

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Co-FounderMr. Michael S. Richman MSBA

Chief Operating OfficerDr. Timothy Mayer Ph.D.

Ph.D.Dr. Lieping Chen M.D.

Chief Financial OfficerMr. Steven P. Cobourn CPA

Senior VP & General CounselMr. Kevin G. Shaw

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NXTC

Nextcure Inc

Upgrade your Finviz experience